PROCEPT BIOROBOTICS CORPPRCT
ASignal's systematic analysis rates PRCT as Neutral.
Reflects the latest available analysis · analyzed Sep 19, 2026
The case on PRCT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin of 63.36% indicating pricing power
- Low debt-to-equity ratio of 0.23x suggesting solid financial health
- High cash reserves with $227.91M in total cash
- Current ratio of 6.55x indicating strong liquidity position
- Revenue growth of 19.3% year-over-year showing solid top-line expansion
- Negative RSI at 41.87, nearing oversold territory
- Bearish MACD signal with MACD below signal line and negative histogram
- Negative price momentum indicating downtrend
- Negative net and operating margins (-32.53% and -32.05%)
- Negative return on equity (-30.24%) and return on assets (-14.75%)
- Negative operating and free cash flows
See the full verdict on PRCT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PRCT
Most investors never get a second opinion, let alone several. ASignal runs PRCT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.